REGENXBIO Inc. RGNX

7.40 0.16 2.21% as of 25 Sep
Market cap
$487.8M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
(193.88) (227.10) (263.49) (280.32) 127.84 (111.25) (94.73) 99.94 (73.17) (62.97)
Depreciation & Amortization
15.62 16.22 18.01 17.62 15.41 9.49 5.96 4.74 4.50 2.55
Non Cash Items (Other)
42.52 32.23 37.97 41.24 35.41 33.48 (13.60) 7.75 9.78 6.63
Accounts Receivable Change
(7.66) 9.71 3.94 4.82 14.12 (9.90) (8.62) (16.80) 0.56 1.07
Accounts Payable Change
(2.28) (0.29) (2.79) 18.79 (2.30) 3.87 1.53 (0.22) 2.62 0.19
Change in payables and accrued liability
0.23 (12.12) 2.45 (25.62) 29.91 17.40 6.88 7.58 1.90 3.87
Change in other assets and liabilities
21.50 8.24 (14.48) 15.98 (1.50) 2.84 (5.11) 1.67 (4.18) 0.10
Operating Cash Flow
(123.96) (173.12) (218.41) (207.49) 218.88 (54.06) (107.70) 104.65 (57.99) (48.56)
Capital expenditures
(2.41) (2.44) (9.96) (30.72) (84.17) (26.87) (11.72) (13.28) (7.16) (8.15)
Short Term Investments Change (Net)
(13.45) 105.88 200.90 18.80 (322.47) 147.34 105.28 (266.08) 2.37 27.54
Long-Term Investments Change (Net)
— — — — — 2.29 — — — —
Investing cash flow
(15.87) 103.45 190.94 (11.93) (406.64) 122.76 93.56 (279.36) (4.79) 19.39
Equity Repurchase (Common, Net)
1.37 133.77 8.22 4.55 222.49 7.42 8.38 205.06 85.04 0.18
Other financial activities
115.41 (41.09) (43.19) (33.39) (27.24) 192.79 (14.80) (0.62) (0.44) (0.06)
Financing cash flow
116.77 92.68 (34.97) (28.84) 195.25 200.21 8.38 204.44 84.60 0.12
Change in Cash
(23.06) 23.00 (62.43) (248.26) 7.48 268.91 (5.77) 29.73 21.82 (29.05)
Beginning Cash
59.56 36.55 98.98 347.24 339.76 70.84 76.61 46.88 25.07 54.12
Ending Cash
36.50 59.56 36.55 98.98 347.24 339.76 70.84 76.61 46.88 25.07
Stock Based Compensation
34.56 38.46 40.27 40.79 38.81 31.95 26.85 16.64 10.61 7.03
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
11.78 5.53 (10.89) 13.98 40.22 14.22 (5.32) (7.77) 0.90 5.23
Investments Change (Net)
(13.45) 105.88 200.90 18.80 (322.47) 149.63 105.28 (266.08) 2.37 27.54
Issuance/Purchase of Shares
1.37 133.77 8.22 4.55 222.49 7.42 8.38 205.06 85.04 0.18
Other line items
Revenue per Employee
0.46 0.24 0.26 0.28 1.26 0.51 0.14 1.14 0.07 0.04

Fold the line items

In millions of $ except per-share values · columns are period end dates